Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

Pfizer invests $25 million in Ribon

by Gina Vitale
February 3, 2023 | A version of this story appeared in Volume 101, Issue 5

 

Pfizer has invested $25 million in Ribon Therapeutics, a small-molecule drug developer targeting stress support pathways. Ribon intends to put the funds toward the clinical development of two small-molecule inhibitors, one in oncology and one in immunology. A Pfizer exec will also join Ribon’s advisory board as part of the investment. In November 2022, Boehringer Ingelheim agreed to acquire one of Ribon’s preclinical programs for an undisclosed amount.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.